Cargando…
Terazosin Stimulates Pgk1 to Remedy Gastrointestinal Disorders
Gastrointestinal disease is the most common health concern that occurs due to environmental, infectious, immunological, psychological, and genetic stress. Among them, the most frequent diseases are gastric ulcer (GU) and ulcerative colitis (UC). DSS-induced UC and ethanol-stimulated GU models resemb...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745693/ https://www.ncbi.nlm.nih.gov/pubmed/35008842 http://dx.doi.org/10.3390/ijms23010416 |
_version_ | 1784630407041384448 |
---|---|
author | Liu, Jingjing Zhao, Wenyang Li, Chun Wu, Tongyu Han, Liang Hu, Zhuozhou Li, Xiangxiang Zhou, Jing Chen, Xinping |
author_facet | Liu, Jingjing Zhao, Wenyang Li, Chun Wu, Tongyu Han, Liang Hu, Zhuozhou Li, Xiangxiang Zhou, Jing Chen, Xinping |
author_sort | Liu, Jingjing |
collection | PubMed |
description | Gastrointestinal disease is the most common health concern that occurs due to environmental, infectious, immunological, psychological, and genetic stress. Among them, the most frequent diseases are gastric ulcer (GU) and ulcerative colitis (UC). DSS-induced UC and ethanol-stimulated GU models resemble the pathophysiology of human gastrointestinal disease. The current study was designed to explore the anti-oxidation, anti-inflammation, anti-cell death properties of terazosin, an α-adrenergic receptor antagonist, in vivo and in vitro. Our results indicate that terazosin dramatically activates Pgk1, and upregulates glycose metabolism, evidenced by the enhanced ATP production and higher LDH enzymatic activity. Also, terazosin significantly enhances p-AKT expression and inhibits NF-κB p65 activation through abrogating the phosphorylation of IKBα, as well as lowers Caspase-1 and GSDMD expression. The findings in this study demonstrate that terazosin exhibits anti-inflammatory effects by downregulating NF-κB-GSDMD signal pathway, along with enhancing glycolysis for gastrointestinal disease treatment. Meanwhile, we also find terazosin ameliorates ethanol-induced gastric mucosal damage in mice. Collectively, as a clinical drug, terazosin should be translated into therapeutics for gastrointestinal disease soon. |
format | Online Article Text |
id | pubmed-8745693 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87456932022-01-11 Terazosin Stimulates Pgk1 to Remedy Gastrointestinal Disorders Liu, Jingjing Zhao, Wenyang Li, Chun Wu, Tongyu Han, Liang Hu, Zhuozhou Li, Xiangxiang Zhou, Jing Chen, Xinping Int J Mol Sci Article Gastrointestinal disease is the most common health concern that occurs due to environmental, infectious, immunological, psychological, and genetic stress. Among them, the most frequent diseases are gastric ulcer (GU) and ulcerative colitis (UC). DSS-induced UC and ethanol-stimulated GU models resemble the pathophysiology of human gastrointestinal disease. The current study was designed to explore the anti-oxidation, anti-inflammation, anti-cell death properties of terazosin, an α-adrenergic receptor antagonist, in vivo and in vitro. Our results indicate that terazosin dramatically activates Pgk1, and upregulates glycose metabolism, evidenced by the enhanced ATP production and higher LDH enzymatic activity. Also, terazosin significantly enhances p-AKT expression and inhibits NF-κB p65 activation through abrogating the phosphorylation of IKBα, as well as lowers Caspase-1 and GSDMD expression. The findings in this study demonstrate that terazosin exhibits anti-inflammatory effects by downregulating NF-κB-GSDMD signal pathway, along with enhancing glycolysis for gastrointestinal disease treatment. Meanwhile, we also find terazosin ameliorates ethanol-induced gastric mucosal damage in mice. Collectively, as a clinical drug, terazosin should be translated into therapeutics for gastrointestinal disease soon. MDPI 2021-12-30 /pmc/articles/PMC8745693/ /pubmed/35008842 http://dx.doi.org/10.3390/ijms23010416 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Liu, Jingjing Zhao, Wenyang Li, Chun Wu, Tongyu Han, Liang Hu, Zhuozhou Li, Xiangxiang Zhou, Jing Chen, Xinping Terazosin Stimulates Pgk1 to Remedy Gastrointestinal Disorders |
title | Terazosin Stimulates Pgk1 to Remedy Gastrointestinal Disorders |
title_full | Terazosin Stimulates Pgk1 to Remedy Gastrointestinal Disorders |
title_fullStr | Terazosin Stimulates Pgk1 to Remedy Gastrointestinal Disorders |
title_full_unstemmed | Terazosin Stimulates Pgk1 to Remedy Gastrointestinal Disorders |
title_short | Terazosin Stimulates Pgk1 to Remedy Gastrointestinal Disorders |
title_sort | terazosin stimulates pgk1 to remedy gastrointestinal disorders |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745693/ https://www.ncbi.nlm.nih.gov/pubmed/35008842 http://dx.doi.org/10.3390/ijms23010416 |
work_keys_str_mv | AT liujingjing terazosinstimulatespgk1toremedygastrointestinaldisorders AT zhaowenyang terazosinstimulatespgk1toremedygastrointestinaldisorders AT lichun terazosinstimulatespgk1toremedygastrointestinaldisorders AT wutongyu terazosinstimulatespgk1toremedygastrointestinaldisorders AT hanliang terazosinstimulatespgk1toremedygastrointestinaldisorders AT huzhuozhou terazosinstimulatespgk1toremedygastrointestinaldisorders AT lixiangxiang terazosinstimulatespgk1toremedygastrointestinaldisorders AT zhoujing terazosinstimulatespgk1toremedygastrointestinaldisorders AT chenxinping terazosinstimulatespgk1toremedygastrointestinaldisorders |